Tofogliflozin hydrate Catalog No.:M10025-2 LY2784544 was used at 5-10

LY2784544 was used at 5-10 µM final concentration in vitro and in cellular assays

Hypoxia-inducible factor-1 alpha is involved in RIP-induced necroptosis caused by in vitro and in vivo ischemic brain injury

GSK180736A is a compound structurally similar to paroxetine that is developed as a ROCK inhibitor

Formula: C40H56

24-48 hours) inhibits LnCAP and MCF7 cells viability in a dose-dependent manner

Tofogliflozin hydrate Catalog No.:M10025-2 LY2784544 was used at 5-10Tofogliflozin, also known as CSG 452, is a potent and high selective SGLT2 inhibitor under development the treatment of diabetes mellitus. Tofogliflozin improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus. Tofogliflozin dose dependently suppressed glucose entry into tubular cells. High glucose exposure (30 mM) for 4 and 24 h significantly increased oxidative stress generation in tubular cells, which were